SARS nucleic acid vaccine and preparation method, application of S gene in coronavirus

A nucleic acid vaccine and vaccine technology, applied in the fields of botanical equipment and methods, biochemical equipment and methods, pharmaceutical formulations, etc., can solve problems such as infection and lack of vaccines

Inactive Publication Date: 2006-09-27
SUN YAT SEN UNIV CANCER CENT
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] According to current research, among the four known structural proteins of coronaviruses, the spike protein (spike S) is a structural protein that induces a protective immune response. The research structure of some scholars has confirmed that the C-terminus of the coronavirus spike protein is Where the antigenic determinant is located, at the same time, SARS-related coronaviruses cause infection through the respiratory tract, and there is still no vaccine that can prevent SARS

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • SARS nucleic acid vaccine and preparation method, application of S gene in coronavirus
  • SARS nucleic acid vaccine and preparation method, application of S gene in coronavirus
  • SARS nucleic acid vaccine and preparation method, application of S gene in coronavirus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Preparation of SARS nucleic acid vaccine:

[0036] Get the SARS-related coronavirus sPike(S F , S N , S M , S C ) gene, amplified by PCR method, after PCR, digested with EcoR1, and simultaneously digested pcDNA3 (see image 3 , Figure 4 ), connected, transformed into Escherichia coli, using ampicillin (Amp r ) resistance screening positive clones (see Figure 5 , Image 6 ), cultivated, purified, and prepared to obtain the SARS nucleic acid vaccine.

[0037] The dosage form is injection.

[0038] The SARS vaccine contains SARS-associated coronavirus S gene and pcDNA3 plasmid. Cloned to pcDNA3 is the full length of the S gene of SARS-associated coronavirus.

[0039] Cloned into the eukaryotic expression plasmid is SARS-associated coronavirus S gene S 1 region segment.

[0040] Cloned into the eukaryotic expression plasmid is SARS-associated coronavirus S gene S 2 region segment.

[0041] Cloned into the eukaryotic expression plasmid is SARS-associated coro...

Embodiment 2

[0044] The N-terminal fragment of the S gene of SARS-associated coronavirus was cloned into pcDNA3. All the other are with embodiment 1.

Embodiment 3

[0046] The middle fragment of the S gene of SARS-associated coronavirus was cloned into pcDNA3. All the other are with embodiment 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention pertains to biological genetic engineering field, specificly relating to SARS nucleic acid vaccine of adenovirus carrier and preparation method, application of related coronavirus S gene in preparation of the SARS vaccine for preventing SARS. The invention is a nucleic acid vaccine, specificly a nucleic acid vaccine manufactured by extracting the SARS related coronary virus spike protein S gene, cloning it onto the pcDNA3, and then passing through an amplification, purification and preparation process. Compared with the traditional inactivated viral particles vaccine, the invention has a high safety; it is convenient to operate; it can effectively induce the organism to produce the antibody and prevent virus from infection of the organism; and it has an extensive clinical application prospect.

Description

1. Technical field [0001] The invention belongs to the field of biogenetic engineering, in particular to a nucleic acid vaccine for atypical pneumonia (SARS) and a preparation method thereof, and the application of the S gene of SARS-associated coronavirus in preparing a vaccine for preventing SARS. 2. Background technology [0002] The outbreak of atypical pneumonia (atypical pneumonia) began in the Guangdong area of ​​China at the end of last year. At present, the disease has spread to more than 30 countries and regions, and the WHO has named it severe acute respiratory syndrome (severe acute respiratory syndrome, SARS). [0003] At present, scientists from many countries in the world have independently isolated new coronaviruses (coronavirus) from the sera of different patients. The results of virus gene sequence analysis show that they have 50% to 60% homology with known coronaviruses. The World Health Organization (WHO) has announced that the pathogen causing SARS is a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/215A61K48/00A61P31/14A61P11/00C12N15/79C12N15/50
Inventor 曾益新黄文林汪健覃海德刘鹏潘志刚冯启胜李疆黄丽惜张妙华陈丽珍
Owner SUN YAT SEN UNIV CANCER CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap